Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA

被引:0
|
作者
Grohe, C. [1 ]
Tsuboi, M. [2 ]
Wu, Y. [3 ,4 ]
John, T. [5 ]
Majem, M. [6 ]
Wang, J. [7 ]
Kato, T. [8 ]
Goldman, J. [9 ]
Kim, S. [10 ]
Yu, C. [11 ,12 ]
Vu, H. [13 ]
Mukhametshina, G. [14 ]
Akewanlop, C. [15 ]
de Marinis, F. [16 ]
Shepherd, F. [17 ]
Urban, D. [18 ,19 ]
Stachowiak, M. [20 ]
Balanos, A. [20 ]
Huang, X. [20 ]
Herbst, R. [21 ,22 ]
Kern, J. [15 ,23 ]
机构
[1] Evangel Lungenklin Berlin Buch, Berlin, Germany
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[4] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[5] Austin Hlth, Heidelberg, Australia
[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[7] Chinese Acad Med Sci, Beijing, Peoples R China
[8] Kanagawa Canc Ctr, Asahi Ward, Asahi, Japan
[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[10] Asan Med Ctr, Seoul, South Korea
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[13] Cho Ray Hosp, Ho Chi Minh City, Vietnam
[14] Republican Clin Oncol Ctr, Kazan City, Russia
[15] Siriraj Hosp, Bangkok, Thailand
[16] IRCCS, European Inst Oncol Ieo, San Giovanni Rotondo, Italy
[17] Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada
[18] Sheba Med Ctr, Tel Hashomer, Israel
[19] Sackler Fac Med, Tel Hashomer, Israel
[20] Astrazeneca, Cambridge, England
[21] Yale Sch Med, New Haven, CT USA
[22] Yale Canc Ctr, New Haven, CT USA
[23] Kwm Missio Clin, Wurzburg, Germany
来源
PNEUMOLOGIE | 2023年 / 77卷
关键词
D O I
10.1055/s-0043-1760904
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
FV 96
引用
收藏
页码:S17 / S17
页数:1
相关论文
共 50 条
  • [1] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [2] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [3] Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Grohe, C.
    Herbst, R. S.
    Tsuboi, M.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S. -W.
    Marmol, D.
    Rukazenkov, Y.
    Wu, Y. -L.
    Engel-Riedel, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 138 - 138
  • [4] Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA
    John, Thomas
    Herbst, Roy
    Tsuboi, Masahiro
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Marmol, Dominika
    Rukazenkov, Yuri
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 69 - 70
  • [5] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [6] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    De Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [7] Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC) from ADAURA
    John, T.
    Grohe, C.
    Goldman, J.
    De Marinis, F.
    Kato, T.
    Wang, Q.
    Choi, J-H.
    Melotti, B.
    Fidler, M.
    Sainsbury, L.
    Stachowiak, M.
    Taggart, S.
    Wu, Y-L.
    Tsuboi, M.
    Herbst, R. S.
    Tarruella, M. Majem
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1548
  • [8] SOCIETAL ECONOMIC IMPACT OF TREATMENT WITH ADJUVANT OSIMERTINIB IN PATIENTS WITH EARLY-STAGE (IB-IIIA) EGFRm NSCLC
    Bracke, B.
    Flint, I
    McCrea, C.
    Freigofaite, D.
    Hu, Y.
    Verhoek, A.
    VALUE IN HEALTH, 2023, 26 (06) : S107 - S107
  • [9] Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis
    Jie, W.
    Wu, Y-L.
    Lu, S.
    Wang, Q.
    Li, S.
    Zhong, W.
    Wang, Q.
    Li, W.
    Wang, B.
    Chen, J.
    Cheng, Y.
    Duan, H.
    Li, G.
    Shan, L.
    Liu, Y.
    Huang, X.
    Atasoy, A.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S73 - S73
  • [10] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
    Herbst, Roy S.
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Wang, Jie
    Kato, Terufumi
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Yu, Chong-Jen
    Vu, Huu Vinh
    Lu, Shun
    Lee, Kye Young
    Mukhametshina, Guzel
    Akewanlop, Charuwan
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Urban, Damien
    Huang, Xiangning
    Bolanos, Ana
    Stachowiak, Marta
    Tsuboi, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1830 - +